I think what this outlines is immunology is becoming the next gold rush.
It's a great thing for patients, but increases risk for investors. There are a number of biotechs vying for their slice of the pie using similar technology to Prima, Dendreon et al.
We, as investors just have to hope Prima's tech is superior and our head-start gives us enough time to become profitable. Particularly when we apply CVac to other cancers for which we don't have ODS.
I think what this outlines is immunology is becoming the next...
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
30.0¢ |
Change
0.005(1.69%) |
Mkt cap ! $436.3M | |||
| Open | High | Low | Value | Volume |
| 29.5¢ | 31.0¢ | 29.0¢ | $504.5K | 1.673M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 39998 | 30.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 30.5¢ | 3997 | 1 |
View Market Depth
| Last trade - 16.10pm 28/10/2024 (20 minute delay) ? |
| IMM (ASX) Chart |